Q4 2022
Released Mar 10, 2023, before the open
10-K filed Mar 10, 2023, 69 days after period end · 0001493152-23-007178
Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00 derivedno prior Q4 2021 on fileno prior Q3 2022 on file
Net Income-$2.23M-$2.23M derivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$2,560,833N/M
Operating Cash Flowderived-$1,838,914N/M
Free Cash Flowderived-$1,935,646—
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019dderived from reported figures |
|---|---|---|---|---|
| Revenue | $0.00 | — | $0.00 | $0.00 |
| Net Income | -$2.23M | $12.62M | -$4.51M | -$3.29M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lipocine Inc. · CIK 1535955 · Engraved from SEC EDGAR